Overview Mozobil for Autologous Stem Cell Mobilization Status: Completed Trial end date: 2015-05-01 Target enrollment: Participant gender: Summary The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation. Phase: Phase 2 Details Lead Sponsor: Sheba Medical CenterTreatments: JM 3100Plerixafor